lutetium dotatate lu-177 (Lutathera) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Lutetium Lu 177 dotatate binds to somatostatin receptors with highest affinity for subtype 2 receptors (SSRT2). Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized. The beta emission from Lu 177 induces cellular damage by formation of free radicals in somatostatin receptor-positive cells and in neighboring cells. LUTATHERA┬« (lutetium Lu 177 dotatate) is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.   NCATS

  • SMILES: [177Lu+3].CC(O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN3CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC3)C(=O)N[C@@H](CC4=CC=C(O)C=C4)C(=O)N[C@H](CC5=CNC6=C5C=CC=C6)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O
  • InChIKey: MXDPZUIOZWKRAA-PRDSJKGBSA-K
  • Mol. Mass: 1609.542
  • ALogP: Missing data
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

United States

$37407.1400
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

(177lu-dotaotyr3)octreotate | 177lu dota-tate | 177lu-dotatate | 177lu-dota-tate | 177lu-octreotate | (177lutetium-dota(o)tyr3)octreotate | dotatate-177lu | lu177 dota-tate | lu-177 dotate | lutate | lutetium dotatate lu-177

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue